Seeking Alpha

Celsion (CLSN) +3.6% premarket after CEO Michael Tardugno tells Reuters his company has a...

Celsion (CLSN) +3.6% premarket after CEO Michael Tardugno tells Reuters his company has a $1B cancer therapy with its ThermoDox treatment for liver cancer. CLSN, with a market cap of only ~$73M and just 16 employees, aims to place an old cancer drug into a new delivery method and adding heat in a recipe for success that can address a large unmet need in cancer.
Comments (4)
  • As a new investor some 13 years ago I made an initial investment in a small wannabe company called Celsion. Since then I have learned a lot about investing. One of the things I've learned is that in the world of biotechs - Do not rush in where others fear to tread! - There is plenty of time to do a little analysis of both the market and the technology. As you gain a little comfort in those two areas make incremental moves in support of your position and take advantage of the invariable volatility of small caps to incrementally hedge your expectations. Be realistic about those expectations. I was young and foolish back then. Unfortunately I am neither young now or quite so foolish. Those were to good old days!
    20 Jun 2012, 10:10 AM Reply Like
  • Phase 3 to be opened in Dec of this yr. ( if all good ..FDA approval ..early 1st 1/4?) They have cash to fund the company into 3rd 1/4 2013. They have a manufacturer of the Thermadox ...I think it's a Chinese company. Last time the FDA Committee unblinded at the Phase 3 the Committee vote was 100 % to continue the phase 3.
    We'll see .....
    Long CLSN
    dave
    20 Jun 2012, 11:28 AM Reply Like
  • hgsi ring a bell?? This could be...
    25 Jun 2012, 05:25 PM Reply Like
  • with the ceo of celsion saying thermodox is a billion dollar drug, with 35million share of stock out is there anyone that can tell me what the p/e could be if it only does 1/2 billion???
    2 Dec 2012, 08:15 PM Reply Like
DJIA (DIA) S&P 500 (SPY)